Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

Cell phones can disrupt gamma cameras, but should they be banned?

The electromagnetic interference (EMI) emitted by cell phones may negatively impact gamma cameras, according to results of study published in the Journal of Medical Imaging and Radiation Sciences. But does that necessitate an outright ban?

Thumbnail

Contamination of Arizona crematory raises questions of how to manage postmortem radiopharmaceuticals

The body of a 69-year-old male patient treated with lutetium-177 dotate contaminated an Arizona crematorium after radioactive material was found on equipment there, Tech Times reported. The incident has raised questions about the postmortem management of radiopharmaceuticals.

Thumbnail

Department of Energy seeks agreement to produce Mo-99 domestically

The Department of Energy’s National Nuclear Security Administration (NNSA) has chosen four U.S. companies to begin negotiations with in an effort to produce Molybdenum-99 (Mo-99) without the use of highly enriched uranium.

Novel PET/CT tracer safe, effective for diagnosing acute venous thromboembolism

A novel PET/CT imaging agent—18F-GP1—produced a high-quality image and yielded a high detection rate for diagnosing acute venous thromboembolism (VTE), reported researchers of a study featured in the February issue of The Journal of Nuclear Medicine.

Thumbnail

PET technique may allow for earlier measurement of breast cancer therapy effectiveness

A molecular imaging technique using PET technology may improve how the efficacy or failure of hormone therapy is measured for breast cancer patients, according to research published online in the February issue of The Journal of Nuclear Medicine

New PET tracer may improve melanoma detection

A novel radiotracer tested for the first time in humans may help improve the detection of primary and metastatic melanoma, a highly aggressive form of skin cancer, according to a study published in the January issue of the Journal of Nuclear Medicine.

Thumbnail

18F-fluoride PET/CT accurate, reliable for detecting bone metastases

Radiolabeled 18F-fluoride PET/CT proved superior at detecting bone metastases (BM) than a comparative radiotracer, according to a Jan. 14 study published in Clinical Radiology.

Thumbnail

Breast-specific gamma imaging could help predict pathologic response to chemotherapy

Breast-specific gamma imaging (BSGI) outperformed breast MRI in predicting a complete pathologic response to neoadjuvant chemotherapy (NAC) with breast cancer, according to research published online Jan. 8 in the American Journal of Roentgenology.